FRA:NP5 • IT0004147952
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for NEWRON PHARMACEUTICALS SPA (NP5.DE).
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 6.094M 5.76% | 9.057M 48.62% | 51.39M 467.41% | 17.886M -65.20% | 15.03M -15.97% | 17.014M 13.20% | 184.49M 984.34% | 119.22M -35.38% | 176.59M 48.12% | 245.92M 39.26% | 312.77M 27.18% | 343.7M 9.89% | |
| EBITDA YoY % growth | -13.1M -7.84% | -11.428M 12.76% | 26.365M 330.71% | -17.976M -168.18% | -14.178M 21.13% | -8.42M 40.61% | 152.36M 1,909.48% | 132.69M -12.91% | 133.69M 0.75% | 180.58M 35.07% | 207.51M 14.91% | 228.47M 10.10% | |
| EBIT YoY % growth | -13.302M -7.65% | -11.629M 12.58% | 26.173M 325.07% | -13.387M -151.15% | -20.471M -52.92% | -7.905M 61.38% | 152.36M 2,027.39% | 132.69M -12.91% | 133.69M 0.75% | 180.58M 35.07% | 207.51M 14.91% | 227.47M 9.62% | |
| Operating Margin | -218.28% | -128.40% | 50.93% | -74.85% | -136.20% | -46.46% | 82.58% | 111.30% | 75.71% | 73.43% | 66.35% | 66.18% | |
| EPS YoY % growth | -0.98 -16.67% | -0.91 7.14% | 0.85 193.41% | -0.85 -200.56% | -0.99 -15.27% | -0.56 43.58% | 4.77 957.67% | 4.13 -13.37% | 4.56 10.38% | 6.23 36.54% | 7.05 13.30% | 8.22 16.55% |
All data in EUR
| Q4 / 25 | Q2 / 26 | Q4 / 26 | |
|---|---|---|---|
| EPS Q2Q % growth | -0.67 -149.50% | -0.67 -16,602.50% | -0.73 -8.33% |
| Revenue Q2Q % growth | 3.876M -91.92% | 6.732M -43.42% | 9.18M 136.84% |
| EBITDA Q2Q % growth | -11.383M -133.43% | 1.459M 124.92% | N/A |
| EBIT Q2Q % growth | -11.504M -133.98% | -11.835M -98.67% | -10.254M 10.86% |
All data in EUR
10 analysts have analysed NP5.DE and the average price target is 53.22 EUR. This implies a price increase of 209.8% is expected in the next year compared to the current price of 17.18.
NEWRON PHARMACEUTICALS SPA (NP5.DE) will report earnings on 2026-03-24, after the market close.
The consensus EPS estimate for the next earnings of NEWRON PHARMACEUTICALS SPA (NP5.DE) is -0.67 EUR and the consensus revenue estimate is 3.88M EUR.
The expected long term growth rate for NEWRON PHARMACEUTICALS SPA (NP5.DE) is -31.45%.